# A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

> **NCT02340221** · PHASE3 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 631 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Taselisib
- **DRUG:** Placebo
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT02340221
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04-09
- **Primary completion:** 2021-06-29
- **Final completion:** 2021-06-29
- **Target enrollment:** 631 (ACTUAL)
- **Why stopped:** The Sponsor discontinued the manufacturing and development of taselisib due to modest clinical benefit and limited tolerability.
- **Last updated:** 2022-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02340221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02340221, "A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02340221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*